Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 5Plasma cell 1Genitourinary 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Brain Neoplasms 152Glioblastoma 147Glioma 95Neuroblastoma 51Medulloblastoma 33Astrocytoma 28Central Nervous System Neoplasms 27Neoplasms 24Ependymoma 23Sarcoma 22Carcinoma, Non-Small-Cell Lung 22Neurofibromatosis 1 21Melanoma 20Breast Neoplasms 20Rhabdomyosarcoma 18Osteosarcoma 18Sarcoma, Ewing 16Oligodendroglioma 16Lung Neoplasms 16Gliosarcoma 16Rhabdoid Tumor 15Wilms Tumor 13Meningioma 13Hepatoblastoma 13Diffuse Intrinsic Pontine Glioma 13Recurrence 12Neurofibroma, Plexiform 12Neoplasm Metastasis 11Meningeal Carcinomatosis 11Lymphoma, Non-Hodgkin 11

Interventions

cabozantinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Sarcoma, Alveolar Soft Part × CNS × Clear all
NCT02867592 2026-06-11

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
109 enrolled 24 charts
CNSEndocrineGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Wilms Tumor, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Central Nervous System Neoplasms, Hepatoblastoma, Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part, Adrenocortical Carcinoma, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡